profit from every €100 of sales.
€0€100
Vetoquinol SA
€87.20-1.47% today
+4.8% since Dec 23, 25
1-year low €66.101-year high €91.00
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay €17.67 for every €1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Vetoquinol SA sold, what it kept, and what it did with the cash.
Sales went from €540 million in 2022 to €526 million in 2025, with €57.4 million of profit last year.
SalesProfit
Vetoquinol SA handed back 46% of the cash it generated last year.
Buybacks €13M€10M
Free cash flow 2025€51M
Bought back its own shares€13M
Paid as dividends€10M
Cash vs. debt€221M vs. €15M
Vetoquinol SA vs. similar companies
Vetoquinol SA grows in the middle of these 5 and is the cheapest for its profits.
| Company | Profit from €100 of sales | Sales growth a year | Price per €1 of profit |
|---|---|---|---|
| Vetoquinol SA | 17.7× · Fair price | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads Vetoquinol SA's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 540 | 529 | 539 | 526 | |
| 380 | 373 | 387 | 393 | |
| 84 | 78 | 76 | 79 | |
| 116 | 112 | 114 | 116 | |
| 48 | 56 | 59 | 57 | |
| 4.06 | 4.70 | 4.98 | 4.94 | |
| 70.4% | 70.4% | 71.9% | 74.7% | |
| 15.6% | 14.7% | 14.1% | 15.0% | |
| 8.9% | 10.5% | 10.9% | 10.9% |
Balance sheet
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 652 | 692 | 744 | 764 |
| Cash | 94 | 147 | 206 | 221 |
| Total debt | 17 | 18 | 21 | 15 |
| Total liabilities | 167 | 165 | 168 | 172 |
| 485 | 527 | 576 | 591 | |
| 12 | 12 | 12 | 12 | |
| 11.0% | 10.7% | 10.3% | 10.1% | |
| 9.9% | 10.5% | 10.2% | 9.7% |
Cash flow
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 63 | 89 | 86 | 72 | |
| 22 | 19 | 18 | 21 | |
| 40 | 70 | 68 | 51 | |
| Dividends paid | 9 | 9 | 10 | 10 |
| 0 | 0 | 3 | 13 | |
| 0 | 0 | 0 | 0 |
Valuation
- 17.7×
- –
- 2.61
- 1.4×
- 1.9×
- 19.7×
- 7.0×
- 5.1%
- 5.7%
- 1.0%
Profitability
- 74.7%
- 15.0%
- 10.9%
- –
- 10.1%
- 10.5%
- –
- –
- –
- –
Growth
- −0.9%
- +6.8%
- –
- –
- −0.6%
Financial health
- -1.8×
- 0.03
- –
- 65.0×
- 3.08
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 31%of 964
Top 39%of 898
Top 27%of 651
Bottom 15%of 911
Top 23%of 991
1.0%of the share price, paid each year
On $1,000 invested$10a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
18.1% of its profit
Room to growStretchedMore than it earns: 20.3%
News
Donald Trump Claims He'll Become "Mr. Veto" After Midterm Elections, but the Results Put the President and Wall Street in a Precarious SituationYahoo Finance · Nov 8, 2026California Gov. Gavin Newsom bans AI 'robo bosses' in landmark state law, reversing his earlier vetoCNBC · Oct 1, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
3/7Passes 3 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
71Pass
Benjamin Graham
81Pass
Philip Fisher
63Pass
Peter Lynch
28No pass
Joel Greenblatt
44No pass
Charlie Munger
57No pass
Terry Smith
48No pass
Questions about Vetoquinol SA
Is Vetoquinol SA a good stock to buy?
A solid business at a fair price. 3 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Vetoquinol SA AI analysis
What does Vetoquinol SA do?
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It is in Drug Manufacturers - Specialty & Generic, based in Lure, France, with 2,422 employees.
Does Vetoquinol SA pay a dividend?
Yes. At today's price the dividend is 1.0% a year, about 18% of its yearly profit. In 2025 it paid out €10.4 million in dividends.
Is Vetoquinol SA stock halal?
Yes. Vetoquinol SA passes our halal screen: its business is permitted and its debt is 2% of its market value, under the 30% limit. How we check
Who are Vetoquinol SA's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Vetoquinol SA's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.